Chimeric antigen receptor T-cell therapy and cardiovascular outcomes in US Medicare beneficiaries
European Heart Journal
CAR-T cell therapies have transformed the treatment landscape of relapsed haematologic malignancies, yet cardiovascular safety in older populations remains insufficiently characterised.
In this large Medicare-based cohort, major adverse cardiovascular events occurred in 5.8% of patients and were most frequently driven by acute heart failure and stroke. Pre-existing cardiovascular disease, particularly cardiomyopathy, atrial fibrillation, and cerebrovascular disease, significantly increased risk.
Read more about the need for improved cardiovascular risk stratification and targeted preventive strategies in older adults undergoing CAR-T therapy.
